论文部分内容阅读
新药过去是从动物、植物和活细胞培养物中提取得到,或者由化学合成制得。随着遗传工程的兴起,一些具有治疗价值和商品性的药物正应运而生。一、基因产物由基因重组技术而获得的胰岛素和干扰素已经商品化。干扰素很可能有特异的吸引靶位作用(1)在任何单一组织和器官中提取都是无用的(它们不贮藏在组织中),(2)业已证明干扰素的高度纯化十分困难(3)有几种化学上不同类别的激素(或者亚类),(4)为临床实验来确定他们的特别效用需要大量干扰素。生长激素、血清白蛋白、尿激酶、血纤维溶酶原激活剂、因子Ⅷ(血疑因子)和淋巴
New drugs used to be derived from animal, plant and living cell cultures or chemically synthesized. With the rise of genetic engineering, a number of drugs of therapeutic value and commerciality are emerging. First, gene products Insulin and interferon obtained by genetic recombination technology have been commercialized. Interferons are likely to have a specific target attraction (1) Extraction is useless in any single tissue or organ (they are not stored in the tissue), (2) it has proven difficult to highly purify interferon (3) There are several chemically different classes of hormones (or subclasses) and (4) large amounts of interferons are required for clinical trials to determine their particular utility. Growth Hormone, Serum Albumin, Urokinase, Plasminogen Activator, Factor VIII (Blood Susceptibility Factor), and Lymph